Fineline Cube

Follow:
14435 Articles
ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration
CompanyDeals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million
CompanyDeals

Luoxin Pharmaceutical Transfers Equity Stake to Shanghai Pharma for RMB 415 Million

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal
CompanyDeals

Sino Biopharmaceutical on Track to Receive $300M Milestone Payment for PD-1/VEGF Antibody Deal

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China
CompanyDeals

Walvax Expands Rights to Notitia’s Gut Microbiota Therapy in Greater China

Sanofi's SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma
CompanyDrug

Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma

Sandoz to Acquire Evotec's Biologics Unit for $300 Million Expansion
CompanyDeals

Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion

Zhaoke Ophthalmology's Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma
CompanyDrug

Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma

Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion
CompanyDeals

Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion

Lee's Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions
CompanyDeals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines
Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086
CompanyDeals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

HRAIN Biotech's HICARA Approved by NMPA for Relapsed/Refractory LBCL
CompanyDrug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL